Zoledronic acid monohydrate 唑来膦酸一水合物; Zoledronate monohydrate; CGP 42446 monohydrate; CGP42446A monohydrate; ZOL 446 monohydrate|cas:165800-06-6|西域试剂

Zoledronic acid monohydrate 唑来膦酸一水合物; Zoledronate monohydrate; CGP 42446 monohydrate; CGP42446A monohydrate; ZOL 446 monohydrate,98.0%

产品编号：Bellancom-13777A| CAS NO：165800-06-6| 分子式：C₅H₁₂N₂O₈P₂| 分子量：290.10

Zoledronic acid monohydrate 是第三代含氮二磷酸盐，能够抑制破骨细胞介导的骨吸收，同时具有抗肿瘤的活性。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-13777A		￥800.00	杭州北京（现货）
Bellancom-13777A		￥1548.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Zoledronic acid monohydrate 唑来膦酸一水合物; Zoledronate monohydrate; CGP 42446 monohydrate; CGP42446A monohydrate; ZOL 446 monohydrate

产品介绍

Zoledronic Acid monohydrate (Zoledronate monohydrate) 是第三代含氮二磷酸盐，具有高效的抗骨质再吸收活性。Zoledronic Acid monohydrate 能抑制破骨细胞的分化和凋亡。Zoledronic Acid monohydrate 也有抗癌作用。

生物活性

Zoledronic acid monohydrate (Zoledronate monohydrate) is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic acid monohydrate inhibits the differentiation and apoptosis of osteoclasts. Zoledronic acid monohydrate also has anti-cancer effects.

体外研究

Zoledronic Acid monohydrate (0.1-1 µM; 48 hours) increases receptor activator of nuclear factor kB ligand (RANKL) and sclerostin mRNA expressions in osteocyte-like MLO-Y4 cells.
Zoledronic Acid monohydrate increases the expression of osteoclastogenesis supporting factor from MLO-Y4 cells.
Zoledronic Acid monohydrate enhances the RANKL expression via IL-6/ JAK2/STAT3 pathway in MLO-Y4 cells.
Zoledronic Acid monohydrate inhibits osteoclast differentiation and function through the regulation of NF-κB and JNK signalling pathways.
Zoledronic Acid monohydrate (10-100 µM; 1-7 days) markedly reduces the viability of MC3T3-E1 cells^[4].
Zoledronic Acid monohydrate (10-100 µM; 1-7 days) induces apoptosis in MC3T3-E1 cells^[4].
Zoledronic Acid monohydrate (10-100 µM; 4 days) inhibits cell viability due to the induction of apoptosis^[4].
Zoledronic Acid monohydrate exerts inhibitory effects on the differentiation and maturation of MC3T3-E1 cells at concentrations <1 µM^[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[4]

Cell Line:	MC3T3-E1 cells
Concentration:	0.02 µM , 0.1 µM, 1 µM, 10 µM, 100 µM
Incubation Time:	1 day, 3 days, 5 days, 7 days
Result:	Reduced cells viability at 10 µM and 100 µM.

Apoptosis Analysis^[4]

Cell Line:	MC3T3-E1 cells
Concentration:	0.02 µM , 0.1 µM, 1 µM, 10 µM, 100 µM
Incubation Time:	1 days, 4 days, 7 days
Result:	Increased the number of early apoptotic cells and late apoptotic or necrotic cells at dose-dependent and time-dependent (high concentrations).

Western Blot Analysis^[4]

Cell Line:	MC3T3-E1 cells
Concentration:	0.02 µM , 0.1 µM, 1 µM, 10 µM, 100 µM
Incubation Time:	4 days
Result:	Down-regulated the protein level of inactive caspase-3 and up-regulated the protein level of active caspase-3 at the concentrations of 10 and 100 µM.

体内研究
(In Vivo)

Zoledronic Acid monohydrate (0.05 mg/kg; i.p.; weekly; for 3 weeks) increases bone mineral density and content^[5].
Zoledronic Acid monohydrate (0.5-1 mg/kg; i.p.; weekly; for 3 weeks) inhibits both osteoclast and osteoblasts function and bone remodeling in vivo interfering with bone mechanical properties^[5].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Five-week-old C57BL6 mice^[5]
Dosage:	0.05 mg/kg, 0.5 mg/kg, 1 mg/kg
Administration:	Intraperitoneal injection, weekly, for 3 weeks
Result:	Inhibited both osteoclast and osteoblasts function and bone remodeling at 0.5 mg/kg and 1 mg/kg.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Five-week-old C57BL6 mice^[5]
Dosage:	0.05 mg/kg, 0.5 mg/kg, 1 mg/kg
Administration:	Intraperitoneal injection, weekly, for 3 weeks
Result:	Inhibited both osteoclast and osteoblasts function and bone remodeling at 0.5 mg/kg and 1 mg/kg.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Five-week-old C57BL6 mice^[5]
Dosage:	0.05 mg/kg, 0.5 mg/kg, 1 mg/kg
Administration:	Intraperitoneal injection, weekly, for 3 weeks
Result:	Inhibited both osteoclast and osteoblasts function and bone remodeling at 0.5 mg/kg and 1 mg/kg.

性状

Solid

溶解性数据

In Vitro:

H₂O : 14.29 mg/mL (49.26 mM; ultrasonic and adjust pH to 8 with NaOH)

DMSO : < 1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble or slightly soluble)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.4471 mL	17.2354 mL	34.4709 mL
5 mM	0.6894 mL	3.4471 mL	6.8942 mL
10 mM	0.3447 mL	1.7235 mL	3.4471 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： PBS
Solubility: 3.33 mg/mL (11.48 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

*以上所有助溶剂都可在西域网站选购。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

参考文献

. Lianwei Wang, et al. Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review. BMC Cancer. 2020; 20: 1059. [Content Brief]

. Hyung Joon Kim, et al. Zoledronate Enhances Osteocyte-Mediated Osteoclast Differentiation by IL-6/RANKL Axis. Int J Mol Sci. 2019 Mar; 20(6): 1467. [Content Brief]

. Xiao-Lin Huang, et al. Zoledronic acid inhibits osteoclast differentiation and function through the regulation of NF-κB and JNK signalling pathways. Int J Mol Med. 2019 Aug;44(2):582-592. [Content Brief]

[4]. XIN HUANG, et al. Dose-dependent inhibitory effects of zoledronic acid on osteoblast viability and function in vitro. Mol Med Rep. 2016 Jan; 13(1): 613-622. [Content Brief]

[5]. Samantha Pozzi, et al. High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. Clin Cancer Res. 2009 Sep 15;15(18):5829-39. [Content Brief]

[6]. Shea GKH, et al. Oral Zoledronic acid bisphosphonate for the treatment of chronic low back pain with associated Modic changes: A pilot randomized controlled trial. J Orthop Res. 2022 Feb 23. [Content Brief]

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

产品编号(Item Number)

批号(Lot Number)

符号	GHS07
信号词	Warning
危害声明	H315-H319-H335
警示性声明	P305 + P351 + P338
危害码 (欧洲)	Xi
风险声明 (欧洲)	36/37/38
安全声明 (欧洲)	26
危险品运输编码	NONH for all modes of transport
海关编码	2933290090

1. 物质的识别

产品名：	Zoledronic acid monohydrate
CAS号：	165800-06-6
制造商/供应商：	西域试剂网站：www.hzbp.cn 邮件：13911702513@139.com

2. 合成/成分数据

产品名：	Zoledronic acid monohydrate
别名：	Zoledronate monohydrate; CGP 42446 monohydrate; CGP42446A monohydrate; ZOL 446 monohydrate
分子式：	C5H12N2O8P2
分子量：	290.1

3. 急救措施

吸入后：	如果吸入，移至空气新鲜处，如果呼吸困难，给输氧，如呼吸停止，给予人工呼吸。
皮肤接触后：	用大量的水冲洗，移除污染的衣服和鞋子。
眼睛接触后：	检查并取下隐形眼镜，并用大量的水冲洗；呼叫医生。
吞食后：	如果吞食，用大量纯净水漱口；呼叫医生。

4. 消防措施

适当的灭火剂：	雾状水，二氧化碳，干粉或泡沫。
防护设备：	穿戴自给式呼吸器和防护服，以防止与皮肤和眼睛接触。

5. 泄漏应急处理

安全防范措施：	封锁泄漏区域；穿戴自给式呼吸器，防护服和厚橡胶手套。
清洁/收集措施：	使用液体粘合原料（硅藻土，通用粘合剂）吸取精细粉末；使用酒精擦洗表面和设备除去污渍；根据第11条处理被污染的材料。

6. 处理和储存

安全处理说明：	避免吸入和接触皮肤，眼睛及衣物；材料可能略微具有刺激性。
储存：	粉末型式 -20°C 3年；4°C 2年溶于溶剂 -80°C 6个月；-20°C 1个月

7. 接触控制和个人防护

呼吸设备：	NIOSH / MSHA认可的呼吸器。
双手保护：	耐化学腐蚀的橡胶手套。
眼睛防护：	化学安全护目镜。

8. 稳定性和反应活性

稳定性：	按照说明存储是稳定的；避免强氧化剂。
热分解/其他要避免的情况：	避免光和热。

9. 毒性资料

急性毒性：	无可用资料。
主要刺激性影响：	无可用资料。
在皮肤上：	无可用资料。
对眼睛：	无可用资料；可能具有刺激性。

10. 生态资料

一般注意事项：

无可用资料。

11. 废弃处置

按照所在国家，省份，县市和地方的法规处置。

12. 运输信息

正确的运输名称：	无
非危险品运输：	这种物质被视为非危险品运输。

13. 法规信息

尚未有针对此产品作出的化学安全性评估。

14. 其他信息

118072-93-8

~88%

165800-06-6

文献：GADOR S.A. Patent: WO2007/16982 A1, 2007 ; Location in patent: Page/Page column 7-8 ;

上游产品 1
118072-93-8
下游产品 0

[1]. Scheper M, et al. A novel soft-tissue in vitro model for bisphosphonate-associated osteonecrosis. ibrogenesis Tissue Repair. 2010 Apr 1;3:6.

[2]. Wang L, et al. The apoptotic effect of Zoledronic acid on the nasopharyngeal carcinoma cells via ROS mediated chloride channel activation. Clin Exp Pharmacol Physiol. 2018 Jun 8.

Zoledronic acid monohydrate 唑来膦酸一水合物; Zoledronate monohydrate; CGP 42446 monohydrate; CGP42446A monohydrate; ZOL 446 monohydrate,98.0%

Zoledronic acid monohydrate 唑来膦酸一水合物; Zoledronate monohydrate; CGP 42446 monohydrate; CGP42446A monohydrate; ZOL 446 monohydrate

化学品安全说明书(MSDS)

质检证书(COA)

1. 物质的识别

2. 合成/成分数据

3. 急救措施

4. 消防措施

5. 泄漏应急处理

6. 处理和储存

7. 接触控制和个人防护

8. 稳定性和反应活性

9. 毒性资料

10. 生态资料

11. 废弃处置

12. 运输信息

13. 法规信息

14. 其他信息

在线咨询